Possibility of increasing cholesterol efflux by adiponectin and its receptors through the ATP binding cassette transporter A1 in HEK293T cells

Biochemical and Biophysical Research Communications

Volumn 411, Issue 2, 2011, Pages 305-311

  Kitajima, Ken ^a   Miura, Shin Ichiro ^a   Yamauchi, Toshimasa ^b   Uehara, Yoshinari ^a   Kiya, Yoshihiro ^a   Rye, Kerry Anne ^c   Kadowaki, Takashi ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HEART RESEARCH INSTITUTE   (Australia)

Author keywords

ABCA1; AdipoR1; AdipoR2; Cholesterol efflux; RHDL

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CHOLESTEROL; COMPLEMENTARY DNA; HIGH DENSITY LIPOPROTEIN; SHORT HAIRPIN RNA; TRITIUM;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ADIPONECTIN; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; HEK293 CELLS; HUMANS; RECEPTORS, ADIPONECTIN; SCAVENGER RECEPTORS, CLASS B;

EID: 79960841299     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.131     Document Type: Article

References (28)

1. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 2001, 98:2005-2010.
2. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.
3. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
4. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 2003, 278:2461-2468.
5. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277:25863-25866.
6. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
7. Hug C., Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr. Opin. Pharmacol. 2005, 5:129-134.
8. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
9. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006, 580:2917-2921.
10. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006, 116:1784-1792.
11. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
12. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3:35-42.
13. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
14. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 26:439-451.
15. Scherer P.E., Williams S., Fogliano M., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270:26746-26749.
16. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996, 271:10697-10703.
17. Tsuchida A., Yamauchi T., Takekawa S., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005, 54:3358-3370.
18. Stein O., Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999, 144:285-301.
19. von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 2001, 21:13-27.
20. Wan N., Lan D., Chen W., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA 2004, 101:9774-9779.
21. Rye K.A., Garrety K.H., Barter P.J. Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J. Lipid Res. 1992, 33:215-224.
22. Tia L., Luo N., Klein R.L., et al. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009, 202:152-161.
23. Gannage-Yared .M.H., Khalife S., Semaan M., et al. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur. J. Endocrinol. 2006, 155:167-176.
24. Wong N.D., Sciammarella M.G., Polk D., et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J. Am. Coll. Cardiol. 2003, 41:1547-1553.
25. Guan J.Z., Tamasawa N., Murakami H., et al. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 2008, 15:20-25.
26. Hu Y.W., Wang Q., Ma X., et al. ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J. Atheroscler. Thromb. 2010, 17:493-502.
27. Akita N., Tsujita M., Yokota T., et al. High density lipoprotein turnover is dependent on peroxisome proliferator-activated receptor alpha in mice. J. Atheroscler. Thromb. 2010, 7:1149-1159.
28. Nakaya K., Ayaori M., Hisada T., et al. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J. Atheroscler. Thromb. 2007, 14:133-141.